Vectivbio Holding Ag Stock News

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:40 p.m. ET. Company management will also be participating in one-on-one investor meetings at the conference.

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year. Unfortunately for investors, many of the most popular 2021 IPO stocks have performed horribly in the public markets up to this point. Bloated valuations coupled with broad weakness in unprofitable growth stocks has weighed on the share prices of many IPO stocks. The good news for investors: there are now plenty of high-quality stocks to buy at a significant discount to their IPO prices.Here are eight 2021 IPO stocks to buy on the dip, according to Bank of America. VectivBio Holding AG (NASDAQ: VECT ) VectivBio is a clinical-stage biotechnology company focused on next-generation GLP-2 analog apraglutide for treatment of short bowel syndrome intestinal failure (SBS-IF) and acute graft vs. host disease. VectivBio priced its IPO at $17 per share in April 2021, but it has since traded all the way down to $4.50.

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels la

Squarepoint Ops LLC bought a new position in VectivBio Holding AG (NASDAQ:VECT) in the second quarter, HoldingsChannel.com reports. The fund bought 25,000 shares of the companys stock, valued at approximately $292,000. Other institutional investors and hedge funds also recently modified their holdings of the company. Pinz Capital Management LP acquired a new position in shares []

Related Stocks: PHVS , FOLD , KNTE , IOVA , AKUS , LUNG , BSX , VECT , RCKT , ANNX , INZY , PTGX , LEGN , EAR , ABCL , XENT ,

BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for

- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - - Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases -

Company to host an R&D Day on September 21, 2021 Company to host an R&D Day on September 21, 2021

Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities

Paul R. Carter and Murray W. Stewart Elected to the Board of Directors Paul R. Carter and Murray W. Stewart Elected to the Board of Directors

- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021-

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commer

- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on S